Razimax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Razimax

Quick Facts

Property Description
Active Ingredient Azithromycin
Pharmacological Class Macrolide Antibiotic (Azalide)
Primary Forms Tablet, Capsule, Oral Suspension
Origin Semi-synthetic (derived from Erythromycin)
Primary Action Bacteriostatic (inhibits bacterial growth)

What Type of Medicine is Razimax and What is its Composition?

Razimax is a prescription-only, semi-synthetic systemic antibacterial medication containing the active ingredient Azithromycin, frequently administered as the dihydrate form. This compound is structurally classified as an azalide and belongs to the broader macrolide antibiotic class, designed for systemic absorption. Azithromycin's structural modifications provide a distinct advantage over older macrolides by enhancing tissue penetration. The substance is categorized as an essential medicine for treating bacterial infections. Razimax is formulated as a single-component product, focusing exclusively on the delivery of Azithromycin.

Available Forms and the Primary Goal of Razimax

Razimax is manufactured in several distinct pharmaceutical preparations for systemic use, most commonly as film-coated tablets, capsules, and a powder for oral suspension. For hospital settings, it is also available as a solution for intravenous injection. The primary goal of Razimax is to alleviate illness caused by bacterial infections by inhibiting the pathogen's ability to reproduce. Azithromycin achieves this by interfering with the bacteria's essential protein production machinery, which functions as a bacteriostatic agent to suppress the growth and spread of infection. This is accomplished by targeting the bacterial ribosome. This action is specific to bacterial cell processes, confirming the drug is not effective against illnesses caused by viruses, such as the common cold or influenza.

What side effects are possible with Razimax?

Official Safety Profile of Razimax (Azithromycin)

The safety profile of Razimax, a macrolide antibiotic, is structured in regulatory documents according to the frequency and nature of the documented adverse reactions. These classifications reflect how government regulatory documents organize and communicate the medicine’s risk profile, spanning multiple System-Organ Classes (SOCs), notably the Gastrointestinal, Nervous System, and Cardiac domains.

Common adverse reactions officially listed in regulatory documents include gastrointestinal effects such as diarrhea, nausea, abdominal pain, and vomiting, along with headache and fatigue. Reactions classified as Uncommon include various infections (e.g., candidiasis), allergic reactions (e.g., rash, pruritus), and neurological effects like dizziness and somnolence.

Serious adverse reactions are prominently highlighted in the official labeling. These include the risk of QT Prolongation and potential for severe ventricular arrhythmias like Torsades de pointes, sometimes resulting in cardiovascular death. Severe hepatotoxicity, including fatal hepatic failure and cholestatic jaundice, is also documented. Other critical risks are severe cutaneous reactions (e.g., Stevens-Johnson Syndrome) and Clostridioides difficile-Associated Diarrhea (CDAD).

Specific safety considerations address vulnerable patient groups. For neonates, a risk of Infantile Hypertrophic Pyloric Stenosis (IHPS) is noted. Older adults may be more susceptible to cardiac risks. Furthermore, regulatory notes indicate that the risk of acute cardiovascular death may be greater during the first five days of use, and caution is required in patients with pre-existing hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Razimax, a medication in the benzodiazepine class, can lead to a state of central nervous system (CNS) depression. Isolated overdose often results in mild to moderate symptoms, but severe toxicity is possible and constitutes a medical emergency.

Documented Overdose Symptoms Severe Overdose Manifestations
Extreme drowsiness, confusion Prolonged deep coma, respiratory arrest
Slurred speech, impaired balance Profound hypotension (low blood pressure)
Lack of coordination (ataxia) Bradycardia (slow heart rate), death

When Immediate Medical Help is Required

Call 911 or emergency medical services immediately if you suspect a Razimax overdose or if the person exhibits any of the following signs:

  • They are unresponsive, cannot be woken up, or have collapsed.
  • They are experiencing shallow or slow breathing, or have stopped breathing.
  • They have had a seizure.

Overdose Risk Factors

The risk of severe overdose and life-threatening respiratory depression is significantly increased when Razimax is taken in combination with other central nervous system depressants, most notably alcohol and opioid medications.

In a hospital setting, the primary management of overdose involves supportive care, including close monitoring of vital signs and ensuring an open airway. The use of the antidote flumazenil may be considered in certain situations, but it is not recommended for routine use in all overdose cases due to associated risks.

Therapeutic Uses of Razimax

Main Uses and Benefits of Razimax (Azithromycin)

Razimax is a systemic antibacterial medication primarily used to provide therapeutic support across several domains of bacterial infection, aiming to ease the overall symptom burden and contribute to easing the overall symptom load. This medication is utilized for a wide range of conditions marked by increased physiological stress.


Therapeutic Indications and Symptom Management

The medication is applied in clinical settings that involve acute or unstable symptom patterns, including the management of community-acquired pneumonia, acute exacerbations of chronic bronchitis, streptococcal pharyngitis or tonsillitis, acute sinusitis, and middle ear infections (otitis media). It is also relevant for uncomplicated skin infections and achieving symptomatic management in specific sexually transmitted infections (STIs). The use of Razimax assists in managing these infectious processes and is commonly used in situations involving certain distressing symptoms, helping to address symptom clusters related to inflammatory states, such as localized pain, fever, and severe cough with purulent discharge.

For patients with chronic lung conditions like Cystic Fibrosis and Bronchiectasis, Razimax is commonly used in situations involving certain distressing symptoms as a long-term supportive measure. It is applied in addressing symptom clusters related to heightened physiological activity during exacerbations, which helps improve day-to-day comfort and assists with maintaining functional stability over time.


QuickFact Block

Property Description
Quick Fact: Addressing Respiratory Strain Helps address symptoms related to acute cough, purulent discharge, and symptoms related to increased physiological activity associated with bacterial infections.
Quick Fact: Context of Use Commonly used for acute symptomatic episodes and as a long-term supportive measure in chronic lung disease.
Quick Fact: Primary Benefit Provides support that helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Razimax?

This section outlines the official eligibility rules for Razimax (Azithromycin) based on government regulatory documentation.


Populations Who Must Not Use Razimax (Contraindications)

Use of Razimax is absolutely prohibited for individuals with a known hypersensitivity or allergic reaction to azithromycin, erythromycin, or any macrolide/ketolide drug. It is also contraindicated for patients with a history of cholestatic jaundice or hepatic dysfunction specifically associated with prior azithromycin use.


Eligibility and Restrictions by Age and Condition

Population Group Official Eligibility/Status
Pediatric Use (Infants) Not established in patients under 6 months of age. Caution is required in neonates due to the risk of Infantile Hypertrophic Pyloric Stenosis.
Severe Organ Impairment Use is restricted or requires caution in severe renal impairment (GFR < 10 mL/min) and in those with severe liver disease.
Cardiac Conditions Caution is mandatory for patients with a known or congenital QT prolongation or other proarrhythmic heart conditions.
Pregnancy and Lactation Use is conditional: only if clearly needed and the potential benefit justifies the risk. The drug is present in breast milk, requiring monitoring of the infant.

Eligibility is also limited for oral formulations in pneumonia patients with complicating risk factors such as known bacteremia, requiring them to use alternative therapies.

What should I know about interactions with other medicines?

Razimax Interactions with other medicines and products

Razimax’s interaction profile is primarily defined by its effects on drug transport and pharmacodynamic risk, rather than significant cytochrome P450 enzyme inhibition. Co-administration with the antipsychotic medicine Pimozide is formally contraindicated due to the risk of serious cardiac events resulting from additive QT interval prolongation. Regulatory documents also caution that concurrent use with Ergot Derivatives is not recommended.

Officially Documented Interaction Patterns:

  • Transporter Inhibition: Razimax is an inhibitor of P-glycoprotein, which results in the increased systemic exposure of co-administered P-gp substrate medicines like Digoxin and Colchicine. Official labeling requires therapeutic drug monitoring for these substances.
  • Altered Coagulation: Co-administration with coumarin-type oral anticoagulants (e.g., Warfarin) may increase coagulation times, necessitating mandatory prothrombin time monitoring.
  • Absorption Interference: Antacids containing aluminum or magnesium hydroxide reduce the Azithromycin peak concentration (Cmax) by approximately 24%. To manage this, an administration separation of at least 2 hours is officially required.
  • Exposure Modification: Co-administration with Nelfinavir results in a formal increase in Azithromycin serum concentrations. Furthermore, food intake increases the Cmax of Azithromycin oral forms, though overall exposure (AUC) remains unchanged.

Regulatory data indicates that patients with severe renal impairment (GFR < 10 mL/min) experience a 33% increase in overall Azithromycin systemic exposure.

Mechanism of Action

How Razimax Works: Mechanism of Action

Razimax, containing Azithromycin, exerts its function through a dual mechanism involving pathogen inhibition and host pathway modulation. The core mechanism is defined by the high-affinity binding of the molecule to the 50S bacterial ribosomal subunit, specifically occluding the peptide exit tunnel on the 23S ribosomal RNA. This interaction acts as an inhibitor of protein synthesis, immediately halting the elongation of nascent polypeptide chains and resulting in a bacteriostatic suppression of bacterial growth and replication.

Beyond this primary action, Azithromycin also functions as a modulator of the host's inflammatory response by inhibiting key signaling cascades, such as the activation of NF-kappaB. This mechanism decreases the synthesis of pro-inflammatory cytokines (e.g., IL-8 and TNF-alpha) and suppresses immune cell chemotaxis, contributing to the attenuation of prolonged or excessive inflammation.

A unique mechanistic feature is the molecule's ability to accumulate in high concentrations within phagocytic immune cells. These cells serve as mobile carriers, ensuring that a sustained, high pharmacological concentration is delivered and maintained at the required tissue site, supporting prolonged biological interaction.

Dosage and Administration Information

How Razimax is Used: Administration Guidelines

Razimax (Azithromycin) is used according to strict, time-defined protocols that depend on the specific infection being addressed. Administration occurs through two primary routes: oral (using tablets, capsules, or suspension) and intravenous (IV) infusion. The IV route is reserved for initial therapy in severe infections, followed by a transition to oral administration to complete the total defined treatment course. For acute infections, the typical usage frequency is once daily.


Standard Dosage Regimens (Adults)

The medicine is prescribed in short, fixed-duration courses, with the total cumulative dose being the governing factor.

Regimen Type Dosage Pattern Duration
Standard 5-Day Course 500 mg on Day 1, followed by 250 mg on Days 2–5 5 Days
Standard 3-Day Course 500 mg once daily 3 Days
Single-Dose Course 1 gram (1000 mg) or 2 grams (2000 mg) total dose 1 Day

Contextual Use and Administration

Administration instructions are form-specific. Razimax tablets and oral suspension may generally be taken with or without food. However, if the formulation is a capsule, the medication is taken at least one hour before or two hours after a meal. IV administration necessitates reconstitution and further dilution of the powdered form, and the resulting solution must be infused over a period of at least 60 minutes; rapid injection is prohibited. No dosage adjustment is required for patients with mild to moderate renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Razimax

This information summarizes the structure of the clinical research and the types of evidence available for Azithromycin (Razimax). It focuses on what types of studies were conducted, what outcomes were monitored by researchers, and what limitations or uncertainties remain in the evidence base. This summary does not provide individual medical advice or recommend a course of action.


Evidence for Acute Respiratory and Ear Infections (CAP, AECB, Otitis Media)

Research has explored the drug's use in conditions such as Community-Acquired Pneumonia (CAP) and Acute Exacerbations of Chronic Bronchitis (AECB) through short-term Randomized Controlled Trials (RCTs). Studies monitored outcomes related to systemic or functional imbalance, including measured hospital stay duration and how quickly patients was monitored for clinical stability. Research highlights changes measured during the study period, including instances of pathogen clearance for susceptible bacterial strains.

For Middle Ear Infections (Acute Otitis Media), studies observed responses in pediatric populations, noting the status of clinical improvement that was observed. Follow-up durations were limited in many of these acute infection studies, meaning the ultimate long-term outcomes are not fully established.


Long-Term Studies and Supportive Use in Chronic Lung Conditions

For chronic conditions like Cystic Fibrosis and Bronchiectasis, research examined long-term use (spanning 6 to 12 months) as a supportive measure. Primary outcomes monitored included exacerbation frequency (how often flare-ups occurred) and changes in lung function, measured using metrics like FEV1. Findings describe patterns related to the frequency of acute exacerbations that were monitored over the observation period in the groups that received the drug. However, data for certain groups remain limited, and the potential for the development of antibiotic resistance over time requires continued monitoring.

Key Studies & References

  1. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections
  2. Cardiovascular Events and Safety Outcomes Associated with Azithromycin Therapy: A Meta-Analysis of Randomized Controlled Trials
  3. Long-term Azithromycin in Children With Bronchiectasis Unrelated to Cystic Fibrosis: Treatment Effects Over Time (Secondary analysis of RCT)
  4. WHO Guidelines for the Treatment of Chlamydia trachomatis: RECOMMENDATIONS FOR TREATMENT OF CHLAMYDIAL INFECTIONS
  5. AZITHROMYCIN tablet, film coated AZITHROMYCIN powder, for suspension - DailyMed (US Regulatory Labeling)

Frequently Asked Questions (FAQ)

Common questions about Razimax (FAQ)

Q: Is Razimax the same type of medicine as [similar drug name]?

A: Razimax contains the active ingredient Azithromycin, which belongs to the macrolide class of antibiotics, specifically classified as an azalide. Official product information notes that other macrolide antibiotics exist, and while they may share some similarities, their structures and uses may differ from Azithromycin.

Q: Can Razimax be taken with common over-the-counter pain relievers?

A: Regulatory documents include warnings for interactions with specific prescription medicines, such as certain heart medications and blood thinners. The official labeling does not list common, non-prescription pain relievers like acetaminophen or ibuprofen as known or named interactions.

Q: Can Razimax interact with herbal supplements?

A: Official regulatory documents list known drug-to-drug interactions, but they do not provide a systematic assessment of all possible interactions with herbal supplements. Patients are generally advised to inform their healthcare provider about all co-administered products, including herbal supplements and vitamins.

Q: Will Razimax interfere with my birth control pills?

A: The official drug labeling for Razimax does not list oral contraceptives (birth control pills) as a known or clinically significant interaction. The potential risks of all medications are best understood through consultation with a healthcare provider.

Q: What were the key findings in the clinical trials for Razimax?

A: Studies and official information indicate that clinical trials found Azithromycin led to measured clinical stability, overall improvement, and/or pathogen clearance in patients with susceptible bacterial infections, depending on the condition being studied.

Q: Can Razimax be taken if I have a history of heart problems?

A: Official product information carries a Warning for the risk of QT prolongation, which is a specific change in the heart's electrical rhythm. Regulatory warnings indicate that use of this medicine requires caution for patients with a known history of this condition or other proarrhythmic heart conditions.

Q: Do I need to take Razimax with food, or can I take it on an empty stomach?

A: This depends on the form of the medication. Most formulations, such as tablets and the liquid suspension, can generally be taken with or without food. However, official instructions require that the capsule form of Azithromycin be taken on an empty stomach, separated from food by at least one to two hours.

Q: Is it normal to have mild nausea when starting Razimax?

A: Nausea is officially listed in regulatory documents as a very common adverse reaction. While official information doesn't specify if it's more frequent when starting, it is one of the most frequently reported digestive side effects.

Q: How does the mechanism of action of Razimax compare to older treatments?

A: Razimax (Azithromycin) is a derivative of Erythromycin (an older macrolide). Its structural modifications give it a unique pharmacokinetic advantage, enabling it to achieve enhanced and sustained concentrations within body tissues and immune cells.

Q: What should I do if I get an allergic reaction after taking Razimax?

A: Official labeling advises that the medication be immediately discontinued if signs of an allergic reaction occur. Regulatory guidelines emphasize that appropriate medical therapy should be instituted. Due to the drug's long half-life, allergic symptoms can sometimes reappear or persist even after stopping the medicine.

Q: Is it okay to drive or operate machinery after taking Razimax?

A: Reported side effects include dizziness and somnolence (drowsiness). Official labeling advises caution regarding driving or operating machinery for patients who experience these effects.

Q: How quickly should I feel the effects of Razimax after taking it?

A: According to official patient information, people taking the medication should generally begin to feel better during the first few days of treatment. If symptoms do not improve or worsen, contacting a healthcare provider for further evaluation is necessary.

Q: Will Razimax make me feel drowsy or tired?

A: Official regulatory documents list fatigue as a common adverse reaction. Somnolence (drowsiness) is also listed as an uncommon adverse reaction.

Q: Is it safe to drink coffee or caffeine while taking Razimax?

A: Official drug interaction lists do not name caffeine as a substance that must be specifically avoided. Patients typically maintain their usual diet unless specific dietary restrictions are recommended by a healthcare provider.

Q: How long does Razimax stay in your system?

A: Pharmacokinetic studies indicate that Azithromycin has a long elimination half-life, which is approximately 68 hours (nearly three days). This long half-life supports the drug's sustained biological activity.

Q: What happens if I miss a dose of Razimax?

A: Official patient information often suggests that if a dose is missed, it may be taken as soon as it is remembered. However, if the time is close to the next scheduled dose, skipping the missed dose and returning to the regular schedule is advised. Regulatory documents advise against taking a double dose to make up for a missed one.

Q: Can Razimax affect my sleep?

A: Official regulatory documents list insomnia, or difficulty sleeping, as an uncommon adverse reaction. If changes to sleep patterns are noted while taking the medication, consultation with a healthcare provider is recommended.

Q: Is Razimax addictive or habit-forming?

A: The active ingredient, Azithromycin, is an antibiotic. Regulatory documents do not include this medication in controlled substance schedules and it is not typically associated with warnings for addiction or habit formation.

Q: Are there generic versions of Razimax available?

A: Yes, the active ingredient, Azithromycin, is available from many manufacturers in FDA-approved generic forms. These generics are considered therapeutically equivalent to the brand-name product.

Q: What if Razimax doesn't seem to be working for me after a week?

A: Official patient information states that improvement should be felt within the first few days of starting the medication. If symptoms do not improve or worsen after taking the medication, consultation with a doctor is necessary for further guidance.

Q: Are there specific symptoms that mean I should stop taking Razimax?

A: Official labeling advises that the medication be immediately discontinued if signs of a serious allergic reaction, severe liver toxicity, or severe skin reactions (e.g., blistering) are noted. These symptoms are generally considered medical emergencies.

Q: Is Razimax safe for people who have kidney issues?

A: The need for a dosage adjustment is not typically required for patients with mild to moderate kidney impairment. However, regulatory documents caution that patients with severe renal impairment (very poor kidney function) experience increased systemic exposure to the drug.

Q: Do the side effects of Razimax go away over time?

A: Mild side effects are often temporary. However, certain severe reactions, particularly allergic symptoms, have been reported to recur or persist even after the drug has been stopped, requiring prolonged monitoring.

Q: Why do some people experience headaches when taking Razimax?

A: Headache is officially listed in regulatory documents as a common adverse reaction. While the exact reason for the drug-induced headache is not typically detailed in the public-facing label, it is a frequently reported side effect.

Q: What are the most serious, but rare, side effects of Razimax?

A: The most serious reactions highlighted in official labeling include the risk of heart rhythm problems (QT prolongation and Torsades de pointes), severe liver failure (hepatotoxicity), and severe skin reactions like Stevens-Johnson Syndrome.

Q: How long does the primary benefit of Razimax typically last after a dose?

A: The drug accumulates in body tissues and has a long half-life of around 68 hours. This pharmacokinetic profile allows for sustained biological activity and prolonged high drug concentrations at the site of infection.

Q: Can Razimax be used during pregnancy or breastfeeding?

A: Use during pregnancy or lactation is considered conditional. It is intended for use only if clearly needed and if the potential benefit justifies the risk. The medication is known to be present in breast milk.

Q: How does body weight affect how Razimax works?

A: Official dosing guidelines indicate that body weight is a crucial factor, particularly for pediatric patients. Dosing for children is typically calculated precisely based on their body weight in milligrams per kilogram (mg/kg).

Q: Can taking Razimax cause stomach upset?

A: Yes, official regulatory documents list several gastrointestinal effects as very common adverse reactions. These include nausea, abdominal pain, and vomiting.

Q: Does Razimax need to be stored in the refrigerator?

A: Tablets and capsules should be stored at controlled room temperature (15 C to 30 C). The mixed liquid suspension generally does not require refrigeration and must be discarded after its specified stability period.

Q: Why is Razimax sometimes prescribed for multiple different conditions?

A: The drug is indicated for several different uses because it is effective against a broad range of susceptible bacterial strains. These bacteria are responsible for various types of infections, including those affecting the respiratory system and the skin.

Q: Will Razimax change my mood or anxiety levels?

A: Official regulatory documents list psychiatric adverse reactions that have been reported, particularly in post-marketing experience. Uncommon reactions include nervousness and insomnia, while anxiety and aggressive behavior have also been reported.

Q: Is Razimax considered a new drug or has it been around for a while?

A: The active ingredient, Azithromycin, is a well-established and essential medicine. It has been in widespread use and FDA-approved since the early 1990s.

How should Razimax be stored and disposed of?

How to Store and Dispose of Razimax (Azithromycin)

Official storage requirements for Razimax depend on the specific formulation. Tablets and capsules must be stored at controlled room temperature (15 C to 30 C), kept in their tightly closed original container, and protected from excess heat, moisture, and light.

Stability and Handling

Dry powder for suspension must be stored below 30 C. Once the powder is mixed, the resulting liquid suspension has a limited in-use stability period; for example, the extended-release suspension must be discarded within 12 hours and should not be refrigerated or frozen. The medicine must be stored out of the reach and sight of children.

Disposal

Any unused or expired product must be disposed of in accordance with local regulatory requirements. Liquid suspensions should be safely discarded after the full course of treatment is complete.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Razimax found in:

A-Z Index: